Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $33,618.60 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 58,980 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $0.57, for a total transaction of $33,618.60. Following the sale, the director directly owned 2,309,869 shares in the company, valued at approximately $1,316,625.33. The trade was a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Luke Evnin also recently made the following trade(s):

• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total value of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.62, for a total transaction of $15,476.44.
• On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total transaction of $21,256.67.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total transaction of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $22,448.16.

Werewolf Therapeutics Stock Up 2.3%

HOWL stock opened at $0.58 on Thursday. The stock has a market capitalization of $28.36 million, a P/E ratio of -0.36 and a beta of 0.77. The firm has a 50-day simple moving average of $0.85 and a 200-day simple moving average of $1.24. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 52 week low of $0.53 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. Equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on HOWL. Wedbush lowered Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective on the stock. in a report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. HC Wainwright dropped their price objective on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Citizens Jmp lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Finally, Citigroup lowered Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $3.75.

Institutional Trading of Werewolf Therapeutics

Hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP raised its position in shares of Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after buying an additional 13,439 shares during the period. Citadel Advisors LLC purchased a new position in shares of Werewolf Therapeutics during the 3rd quarter worth $304,000. Vanguard Group Inc. raised its holdings in Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares during the period. Bridgeway Capital Management LLC raised its holdings in Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after buying an additional 62,414 shares during the period. Finally, Bank of America Corp DE lifted its position in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.